These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35506179)

  • 21. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database.
    Watson L; Das R; Farquhar R; Langerman H; Barnett AH
    Curr Med Res Opin; 2016 Sep; 32(9):1465-75. PubMed ID: 26907851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in clinical characteristics, medication use, and glycemic control in insulin-treated patients with type 1 and type 2 diabetes in Finland in 2012-2019: Nationwide real-world evidence study.
    Niskanen L; Hannula M; Kysenius K; Kaijala S; Lassenius MI; Valle TT
    J Diabetes; 2024 May; 16(5):e13491. PubMed ID: 38273701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the Effect of Early Versus Delayed Metformin Treatment on Glycaemic Parameters Among Australian Adults With Incident Diabetes: Evidence Using a National General Practice Database.
    Zheng M; Begum M; Bernardo CO; Stocks N; Gonzalez-Chica D
    Clin Ther; 2024 May; 46(5):396-403. PubMed ID: 38565499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial.
    van den Burg EL; Schoonakker MP; van Peet PG; van den Akker-van Marle EM; Lamb HJ; Longo VD; Numans ME; Pijl H
    Diabetologia; 2024 Jul; 67(7):1245-1259. PubMed ID: 38546821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes.
    Korytkowski MT; Brooks M; Lombardero M; DeAlmeida D; Kanter J; Magaji V; Orchard T; Siminerio L
    J Diabetes Sci Technol; 2015 May; 9(3):593-601. PubMed ID: 25526759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensification of medical management in type 2 diabetes: A real-world look at primary care practice.
    Zekarias K; Davey C; Seaquist E
    J Diabetes Complications; 2020 Jan; 34(1):107477. PubMed ID: 31711841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000-2019.
    Lee KA; Jin HY; Kim YJ; Im YJ; Kim EY; Park TS
    J Korean Med Sci; 2021 Sep; 36(36):e230. PubMed ID: 34519186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.
    Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA
    Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.
    Datta-Nemdharry P; Thomson A; Beynon J; Donegan K
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):127-135. PubMed ID: 27642000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
    Blonde L; Fainberg U; Kaltoft MS; Mosenzon O; Ramesh C; Rea R
    Diabetes Obes Metab; 2021 Oct; 23(10):2234-2241. PubMed ID: 34132018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.